Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin

被引：0
|
作者：
Andrea D. Fass
Jennifer A. Gershman
机构：
[1] Nova Southeastern University,Department of Pharmacy Practice
[2] College of Pharmacy,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Alogliptin; Combination therapy; Dipeptidyl peptidase-4 inhibitors; Linagliptin; Metformin; Saxagliptin; Sitagliptin; Type 2 diabetes; Vildagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 353
页数：16
相关论文
共 50 条
  • [31] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
    Green, Jennifer B.
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
  • [32] Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure
    Kankanala, Saumya Reddy
    Syed, Rafay
    Gong, Quan
    Ren, Boxu
    Rao, Xiaoquan
    Zhong, Jixin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (05): : 2450 - 2458
  • [33] Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis
    Foroutan, Naghmeh
    Muratov, Sergei
    Levine, Mitchell
    CLINICAL AND INVESTIGATIVE MEDICINE, 2016, 39 (02): : E48 - E62
  • [34] The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Kanasaki, Keizo
    CLINICAL SCIENCE, 2018, 132 (04) : 489 - 507
  • [35] Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho, Y.
    Itoh, H.
    DIABETIC MEDICINE, 2013, 30 (04) : e149 - e150
  • [36] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
    Rankovic, Marina
    Jeremic, Nevena
    Srejovic, Ivan
    Radonjic, Katarina
    Stojanovic, Aleksandra
    Glisic, Milos
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    HEART FAILURE REVIEWS, 2021, 26 (02) : 437 - 450
  • [37] Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
    Makino, Yuichi
    Fujita, Yukihiro
    Haneda, Masakazu
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (01): : 67 - 73
  • [38] Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
    Larry K. Golightly
    Caitlin C. Drayna
    Michael T. McDermott
    Clinical Pharmacokinetics, 2012, 51 (8) : 501 - 514
  • [39] Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
    Shoombuatong, Watshara
    Prachayasittikul, Veda
    Anuwongcharoen, Nuttapat
    Songtawee, Napat
    Monnor, Teerawat
    Prachayasittikul, Supaluk
    Prachayasittikul, Virapong
    Nantasenamat, Chanin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4515 - 4549
  • [40] Effect of dipeptidyl peptidase-4 inhibitors on complement activation
    Hoffmann-Petersen, Ingeborg T.
    Holt, Charlotte B.
    Jensen, Lisbeth
    Hage, Camilla
    Mellbin, Linda G.
    Thiel, Steffen
    Hansen, Troels K.
    Ostergaard, Jakob A.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2021, 37 (03)
12345